Panbela Therapeutics (NASDAQ:PBLA) Shares Down 2.7%

Panbela Therapeutics, Inc. (NASDAQ:PBLA)’s stock price traded down 2.7% on Friday . The stock traded as low as $0.33 and last traded at $0.36. 2,808 shares were traded during trading, a decline of 99% from the average session volume of 281,870 shares. The stock had previously closed at $0.37.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating on shares of Panbela Therapeutics in a research note on Thursday, August 15th.

Panbela Therapeutics Stock Performance

The firm’s 50 day moving average price is $0.36 and its 200-day moving average price is $0.49. The firm has a market capitalization of $1.25 million, a PE ratio of 0.00 and a beta of 1.62.

Panbela Therapeutics (NASDAQ:PBLA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($1.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.07) by $0.60. On average, equities research analysts expect that Panbela Therapeutics, Inc. will post -6.76 earnings per share for the current fiscal year.

About Panbela Therapeutics

Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.